JP2019531293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531293A5 JP2019531293A5 JP2019515467A JP2019515467A JP2019531293A5 JP 2019531293 A5 JP2019531293 A5 JP 2019531293A5 JP 2019515467 A JP2019515467 A JP 2019515467A JP 2019515467 A JP2019515467 A JP 2019515467A JP 2019531293 A5 JP2019531293 A5 JP 2019531293A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- peptide consisting
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 208000035473 Communicable disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000003463 hyperproliferative effect Effects 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395195P | 2016-09-15 | 2016-09-15 | |
| US62/395,195 | 2016-09-15 | ||
| PCT/US2017/051697 WO2018053218A1 (en) | 2016-09-15 | 2017-09-15 | Pd-1 peptide inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531293A JP2019531293A (ja) | 2019-10-31 |
| JP2019531293A5 true JP2019531293A5 (https=) | 2020-11-05 |
| JP6928083B2 JP6928083B2 (ja) | 2021-09-01 |
Family
ID=60009711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515467A Active JP6928083B2 (ja) | 2016-09-15 | 2017-09-15 | Ｐｄ−１ペプチド阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10098950B2 (https=) |
| EP (2) | EP3795167B1 (https=) |
| JP (1) | JP6928083B2 (https=) |
| AU (1) | AU2017325866B2 (https=) |
| CA (1) | CA3036251A1 (https=) |
| DK (2) | DK3512536T3 (https=) |
| WO (1) | WO2018053218A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10799555B2 (en) | 2016-09-15 | 2020-10-13 | Leidos, Inc. | PD-1 peptide inhibitors |
| US10098950B2 (en) | 2016-09-15 | 2018-10-16 | Leidos, Inc. | PD-1 Peptide Inhibitors |
| WO2018218137A1 (en) | 2017-05-25 | 2018-11-29 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| DK3758732T3 (da) * | 2018-02-27 | 2024-10-07 | Leidos Inc | PD-1-peptidinhibitorer |
| CN111647065B (zh) * | 2018-10-30 | 2021-10-08 | 北京永恩堂医学研究院 | 一种改进的能与pd-1特异性结合的肿瘤抑制肽及其用途 |
| CA3185657A1 (en) | 2020-06-04 | 2021-12-09 | Leidos, Inc. | Immunomodulatory compounds |
| EP4225444A1 (en) * | 2020-10-12 | 2023-08-16 | Leidos, Inc. | Immunomodulatory peptides |
| JP2024505274A (ja) | 2021-02-02 | 2024-02-05 | ゲオバックス インコーポレイテッド | ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト |
| CN113336824A (zh) * | 2021-04-30 | 2021-09-03 | 重庆理工大学 | 一种多肽在作为pd-1/pd-l1蛋白-蛋白相互作用(ppi)调节剂中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002513811A (ja) | 1998-05-06 | 2002-05-14 | ファルマシア・アンド・アップジョン・カンパニー | 非−ヒト脊椎動物への、非−ヒト脊椎動物のペプチドホルモンまたはサイトカインをコードする裸のｄｎａまたは裸のｒｎａの導入 |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2012168944A1 (en) | 2011-06-08 | 2012-12-13 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| WO2013132317A1 (en) | 2012-03-07 | 2013-09-12 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
| CA2868408A1 (en) | 2012-03-29 | 2013-10-03 | Aurigene Discovery Technologies Limited | Immunomodulating cyclic compounds from the bc loop of human pd1 |
| US9974845B2 (en) | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| US10098950B2 (en) | 2016-09-15 | 2018-10-16 | Leidos, Inc. | PD-1 Peptide Inhibitors |
| CN107383174B (zh) | 2017-08-21 | 2019-01-18 | 生工生物工程（上海）股份有限公司 | 一种能与pd-1特异性结合的肿瘤抑制肽及其用途 |
-
2017
- 2017-09-15 US US15/705,333 patent/US10098950B2/en active Active
- 2017-09-15 JP JP2019515467A patent/JP6928083B2/ja active Active
- 2017-09-15 EP EP20204314.7A patent/EP3795167B1/en active Active
- 2017-09-15 DK DK17778394.1T patent/DK3512536T3/da active
- 2017-09-15 WO PCT/US2017/051697 patent/WO2018053218A1/en not_active Ceased
- 2017-09-15 AU AU2017325866A patent/AU2017325866B2/en active Active
- 2017-09-15 EP EP17778394.1A patent/EP3512536B1/en active Active
- 2017-09-15 DK DK20204314.7T patent/DK3795167T3/da active
- 2017-09-15 CA CA3036251A patent/CA3036251A1/en active Pending
-
2018
- 2018-03-01 US US15/908,861 patent/US10799581B2/en active Active
-
2020
- 2020-09-21 US US17/026,447 patent/US20210000948A1/en not_active Abandoned
-
2023
- 2023-11-08 US US18/388,036 patent/US20240075131A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531293A5 (https=) | ||
| JP2016539946A5 (https=) | ||
| JP2017524682A5 (https=) | ||
| JP2019511222A5 (https=) | ||
| JP2016538885A5 (https=) | ||
| JP2014521684A5 (https=) | ||
| JP2011250797A5 (https=) | ||
| JP2012136541A5 (https=) | ||
| JP2016128513A5 (https=) | ||
| JP2016506416A5 (https=) | ||
| JP2015533376A5 (https=) | ||
| JP2015517489A5 (https=) | ||
| JP2014169326A5 (https=) | ||
| JP2016535009A5 (https=) | ||
| JP2017537105A5 (https=) | ||
| JP2015517488A5 (https=) | ||
| JP2016516016A5 (https=) | ||
| JPWO2019156137A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| JP2019534003A5 (https=) | ||
| JP2012102105A5 (https=) | ||
| JP2018536002A5 (https=) | ||
| FI3511004T3 (fi) | Yhdistelmävalmisteita syövän hoitoon | |
| RU2016108808A (ru) | Терапевтическое применение vegf-c и ccbe1 | |
| CN111989095A (zh) | 预防或治疗肿瘤疗法副作用的方法 |